Pfizer fight with Starboard heats up, hedge fund alleges executive pressure
The corporate clash between Pfizer and Starboard Value heated up on Thursday when the activist investment firm pressed the U.S. drugmaker to investigate actions by its board, after two former executives backed out of its campaign against the company.
The Washington Post on MSN11h
After Pfizer’s coronavirus vaccine success, CEO targeted for revenue slumpBarely three years since its coronavirus vaccine helped stem the pandemic, Pfizer’s stock has lost 50 percent of its value ...
The activist investment firm Starboard Value has launched a proxy fight again Pfizer, questioning the company’s management ...
The new drug would allow patients to produce the needed clotting protein for an extended period, reducing the need for ...
Starboard Value alleged that Pfizer officials threatened legal action against two former top executives who had been working ...
On Oct. 6, The Wall Street Journal reported that activist investor group Starboard Value owns a stake in Pfizer ( PFE -0.61%) ...
The approval of Hympavzi Friday was a dose of good news for Pfizer, which is dealing with research setbacks and a challenge from an activist investor.
Pfizer’s situation with activist investor Starboard Value is already getting messy. | After initially supporting a meeting ...
Pfizer's Hympavzi receives FDA approval as the first anti-TFPI therapy for hemophilia A and B. This subcutaneous, once-weekly ...
Larry Lowe has suffered excruciating symptoms since he received the vaccine in 2021 and his condition is ‘only going to get ...
Six months after scoring FDA approval for hemophilia B gene therapy Beqvez, Pf | For the second time in six months, the FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback